[en] Anti-TNF agents are highly effective in treating inflammatory bowel diseases, but loss of response and side-effects leading to drug interruption are often reported. New molecules are needed to treat these patients. Vedolizumab is a fully humanized anti-body inhibiting the migration of circulating lymphocytes to the gut by binding the integrin alpha4beta7. In ulcerative colitis, clinical response, remission and mucosal healing were observed at 6 weeks in 47%, 17% and 40% of the patients, respectively. The maintenance study demonstrated 42% and 52% of clinical remission and response at week 52. In Crohn's disease, clinical response and remission were respectively observed in 15% and 31% of the patients at 6 weeks. Clinical remission at week 52 was 39%. The time to clinical response was longer in patients who had failed anti-TNF. The safety profile is excellent with the same proportion of side-effects in the placebo and in the treated groups. The most frequently reported adverse events were pharyngitis and headaches.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Kemseke, Catherine ; Université de Liège > Relations académiques et scientifiques (Médecine)
Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
REENAERS, Catherine ; Université de Liège - ULiège > Relations académiques et scientifiques (Médecine) > Hépato-gastroentérologie
Language :
French
Title :
LE MEDICAMENT DU MOIS. Vedolizumab (Entyvio(R)), nouveau traitement des maladies inflammatoires intestinales.
Alternative titles :
[en] Vedolizumab (Entyvio(R)) for the treatment of inflammatory bowel diseases
Publication date :
2015
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Hanauer S. - Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis, 2006, 12 (Suppl 1), S3-9.
Xavier RJ1, Podolsky DK. - Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007, 448, 427-434.
Allez M, Karmiris K, Louis E, et al. - Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J Crohns Colitis, 2010, 4, 355-366.
D'Haens GR, Panaccione R, Higgins PD, et al. - The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol, 2011, 106, 199- 212.
von Andrian UH, Mackay CR. - T-cell function and migration. Two sides of the same coin. N Engl J Med, 2000, 343, 1020-1034.
Kolachala VL, Bajaj R, Wang L, et al. - Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation. J Biol Chem, 2007, 282, 32965-32973.
Thomas S, Baumgart DC. - Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology, 2012, 20, 1-18.
Henninger DD, Panès J, Eppihimer M, et al. - Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol, 1997, 158, 1825-1832.
Sans M, Panés J, Ardite E, et al. - VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology, 1999, 116, 874-883.
Panès J, Anderson DC, Miyasaka M. - Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats. Gastroenterology, 1995, 108, 1761-1769.
Targan SR, Feagan BG, Fedorak RN, et al. - Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology, 2007, 132, 1672-1683.
Major EO. - Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med, 2010, 61, 35-47.
Feagan BG, Greenberg GR, Wild G, et al. - Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol, 2008, 6, 1370-1377.
Jovani M, Danese S, et al. - Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets, 2013, 14, 1433-1443.
Wyant T, Leach T, Sankoh S, et al. - Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results. Gut, 2015, 64, 77-83.
Feagan BG, Rutgeerts P, Sands BE, et al. - Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013, 369, 699-710.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. - Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med, 2013, 369, 711-721.
Sands BE, Feagan BG, Rutgeerts P, et al. - Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology, 2014, 147, 618-627.
Shelton E, Allegretti JR, Stevens B, et al. - Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis, 2015, Aug 17 [Epub ahead of print] .
Colombel JF, Sands BE, Hanauer SB, et al. - Long term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Am J Gastroenterol, 2013, 108, S502.
Feagan B, Kaser A, Smyth M, et al. - Long term efficacy of vedolizumab therapy for ulcerative colitis (Abstract). Am J Gastroenterol, 2014, 109, S 477.
Hanauer S, Rutgeerts P, Xu J, et al. - Long term efficacy of vedolizumab therapy for Crohn's disease (Abstract). Am J Gastroenterol, 2014, 109, S 479.
Mosli MH, MacDonald JK, Bickston SJ, et al. - Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis. Inflamm Bowel Dis, 2015, 21, 1151- 1159.
Dulai PS, Mosli M, Khanna R, et al. - Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy, 2015, 35, 412-423.
